Qingquan Xiao

Title: Qingquan Xiao: Innovator in CRISPR Technology

Introduction

Qingquan Xiao is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of genetic engineering, particularly through his work on CRISPR technology. With a total of two patents to his name, he is recognized for his innovative approaches to targeting nucleic acids.

Latest Patents

Qingquan Xiao's latest patents include the Type VI-E and Type VI-F CRISPR-Cas systems and their uses. These inventions provide novel CRISPR/Cas compositions designed for targeting nucleic acids. Specifically, they introduce non-naturally occurring or engineered RNA-targeting systems that utilize a novel RNA-targeting Cas13e or Cas13f effector protein. These systems also incorporate at least one targeting nucleic acid component, such as a guide RNA (gRNA) or crRNA. Notably, the Cas effector proteins developed by Xiao are among the smallest known, measuring approximately 800 amino acids in size. This unique characteristic makes them particularly suitable for delivery using vectors of small capacity, such as adeno-associated virus (AAV) vectors.

Career Highlights

Throughout his career, Qingquan Xiao has worked with several notable companies, including Huigene Therapeutics Co., Ltd. and Huidagene Therapeutics (Singapore) Pte. Ltd. His work in these organizations has furthered advancements in therapeutic applications of CRISPR technology.

Collaborations

Qingquan Xiao has collaborated with several professionals in his field, including Chunlong Xu and Yingsi Zhou. These collaborations have contributed to the development and refinement of his innovative technologies.

Conclusion

Qingquan Xiao stands out as a key figure in the advancement of CRISPR technology, with his innovative patents paving the way for future developments in genetic engineering. His contributions are expected to have a lasting impact on the field.